WO1998020340A1 - A dissolution test method for solid steroidal pharmaceutical formulations - Google Patents
A dissolution test method for solid steroidal pharmaceutical formulations Download PDFInfo
- Publication number
- WO1998020340A1 WO1998020340A1 PCT/US1997/020395 US9720395W WO9820340A1 WO 1998020340 A1 WO1998020340 A1 WO 1998020340A1 US 9720395 W US9720395 W US 9720395W WO 9820340 A1 WO9820340 A1 WO 9820340A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polysorbate
- concentration
- dissolution
- measuring
- solid
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N13/00—Investigating surface or boundary effects, e.g. wetting power; Investigating diffusion effects; Analysing materials by determining surface, boundary, or diffusion effects
- G01N2013/006—Dissolution of tablets or the like
Definitions
- the present invention relates to a method for measuring the dissolution rate of a solid steroidal pharmaceutical formulation. More particularly, the invention relates to a method for determining the dissolution rate of the steroids, norgestimate and ethinyl estradiol from tablet formulations.
- a pharmaceutical agent is useless if it cannot be delivered to a biological system at a controlled rate sufficient to elicit and maintain a physiological effect for a desired period of time. Therefore is it imperative to the quality control of drug substances that a pharmaceutical manufacturer reproducibly and reliably test the rate at which a drug substance is released from its formulation.
- the rate at which a drug is released from capsules or tablets to liquid media can be established by in vitro dissolution testing. In this type of test, solid formulations are added to a liquid medium and over time samples are withdrawn then analyzed for the percentage of dissolved drug substance. Studies have shown that in vitro dissolution rates are directly related to efficacy and bioavailability of many pharmaceutical formulations. Due to these results, drug manufacturers routinely use dissolution testing to assure the lot to lot consistency of their product.
- dissolution medium The major component of dissolution medium is water, but often other components are added to increase the comparability of the in vitro dissolution test with a biological system.
- Aqueous HCI, alcohols and surfactants (polysorbate 80) have been added to dissolution media for this purpose.
- in vitro dissolution tests have used isopropanol and water as the dissolution medium. However, for such formulations, these tests have not satisfactorily replicated gastric conditions and have not proven sufficient to reproducibly discern between pharmaceutical formulations whose steroidal dissolution rates decline over time.
- the object of the present invention is to measure the dissolution rate of steroids from their pharmaceutical formulations in a reproducible manner. Where said method distinguishes variations in dissolution behavior between different batches of formulations.
- the invention provides for a method of determining the dissolution rate of a steroid from its solid pharmaceutical formulation. Said method comprises: adding a steroidal formulation to a paddle assembly containing an aqueous solution of polysorbate 20, where the concentration of polysorbate 20 is about 0.025 to about 0.15% weight/volume and the temperature of the assembly is about 37 °C; removing aliquots and measuring the percentage of steroid dissolved in each aliquot.
- the present invention finds that the dissolution medium is critical and controls the composition of the medium, namely the type of water, the surfactant and the solution's concentration.
- the method of preparing the dissolution medium can be critical with some surfactants.
- the surfactant employed is polysorbate 20, a partially esterified cyclic derivative of sorbitol, a natural sugar.
- the surfactant's most popular use is in the preparation of pharmaceutical formulations it may have other uses.
- Polysorbate 20 is commercially available from a number of suppliers and due to the surfactant's susceptibility to degradation over time, USP (23/NF 18) has published standards for determining the suitability of the surfactant. However the published values (hydroxyl, saponification, water, residue on ignition, arsenic, heavy metals and acid content values) do not guarantee suitability of polysorbate 20 for this dissolution test. ( See Donbrow, M. et al Journal of Pharmaceutical Sciences, 67, 12, pgs. 1676-81 1978). Although polysorbate 20 produced by a variety of manufacturers can be used, the preferred surfactant is "fresh" polysorbate 20 as described hereinafter.
- fresh polysorbate 20 polysorbate that is less than 2 years old, which has been stored in the absence of light and has been stored under an inert atmosphere. It is possible to obtain reliable and reproducible dissolution test results using polysorbate 20 that does not meet all three criteria. However, the preferred polysorbate 20 is material that meets all three criteria.
- the type of water, temperature of the dissolution medium and concentration of the surfactant affect dissolution testing.
- the preferred water is helium sparged deionized water, but bottled water may be substituted.
- the preferred temperature of the dissolution medium is about 37 °C. However in vitro dissolution tests may be run from about 34 -42 °C.
- the type of paddle assembly used in the invention's in vitro test may vary, and those skilled in the art of dissolution testing may use apparatuses suitable to their needs. However a USP Paddle Assembly II (Volume 23) is the preferred assembly.
- Table A illustrates that dissolution rates increase with increasing surfactant concentration.
- the data in this table was generated by testing a single lot of steroid with different concentrations of polysorbate 20 in the following manner. Deionized water was premixed with the sufficient polysorbate 20 to give the indicated concentration over 16 h. This solution (600 mL) was placed in each of the reaction vessels of a USP Paddle Assembly II (vol 23/18), stirred at 75 r.p.m. and equilibrated to 37 °C. A norgestimate and ethinyl estradiol formulation was added to each vessel, samples were removed at 20 min and analyzed by routine HPLC methods for the percentage of dissolved norgestimate.
- the first four runs used fresh polysorbate and the last run (*) used 4 year old surfactant.
- the data is represented as both the average % and the range of values obtained. As shown, the concentration of polysorbate 20 which give the narrowest range of values is 0.05% of fresh polysorbate 20. Therefore the preferred concentration of polysorbate 20 is 0.05%.
- the data below was obtained for norgestimate, similar results are expected for ethinyl estradiol, the other steriodal component of the formulation.
- Deionized water was sparged with helium for at least 12 min.
- Fresh polysorbate 20 (3.0 g; Tween ® 20) was placed in a 400 mL beaker and dissolved in sparged water (200 mL) at room temperature with the aid of mechanical stirring. The resulting solution was diluted with sparged water to 6L and stirred overnight at room temperature.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention provides for a method of determining the dissolution rate of a steroid from its solid pharmaceutical formulation. Said method comprises: adding a steroidal formulation to a paddle assembly containing an aqueous solution of polysorbate 20, where the concentration of polysorbate 20 is about 0.025 to about 0.15 % weight/volume and the temperature of the assembly is about 37 °C; removing aliquots and measuring the percentage of steroid in each aliquot.
Description
A DISSOLUTION TEST METHOD FOR SOLID STEROIDAL PHARMACEUTICAL FORMULATIONS
FIELD OF THE INVENTION The present invention relates to a method for measuring the dissolution rate of a solid steroidal pharmaceutical formulation. More particularly, the invention relates to a method for determining the dissolution rate of the steroids, norgestimate and ethinyl estradiol from tablet formulations.
BACKGROUND
A pharmaceutical agent is useless if it cannot be delivered to a biological system at a controlled rate sufficient to elicit and maintain a physiological effect for a desired period of time. Therefore is it imperative to the quality control of drug substances that a pharmaceutical manufacturer reproducibly and reliably test the rate at which a drug substance is released from its formulation. The rate at which a drug is released from capsules or tablets to liquid media can be established by in vitro dissolution testing. In this type of test, solid formulations are added to a liquid medium and over time samples are withdrawn then analyzed for the percentage of dissolved drug substance. Studies have shown that in vitro dissolution rates are directly related to efficacy and bioavailability of many pharmaceutical formulations. Due to these results, drug manufacturers routinely use dissolution testing to assure the lot to lot consistency of their product.
The major component of dissolution medium is water, but often other components are added to increase the comparability of the in vitro dissolution test with a biological system. Aqueous HCI, alcohols and surfactants (polysorbate 80) have been added to dissolution media for this purpose. In the case of steroidal formulations, in vitro dissolution tests have used isopropanol and water as the dissolution medium. However, for such formulations, these tests have not satisfactorily replicated gastric conditions
and have not proven sufficient to reproducibly discern between pharmaceutical formulations whose steroidal dissolution rates decline over time.
The object of the present invention is to measure the dissolution rate of steroids from their pharmaceutical formulations in a reproducible manner. Where said method distinguishes variations in dissolution behavior between different batches of formulations.
SUMMARY OF THE INVENTION The invention provides for a method of determining the dissolution rate of a steroid from its solid pharmaceutical formulation. Said method comprises: adding a steroidal formulation to a paddle assembly containing an aqueous solution of polysorbate 20, where the concentration of polysorbate 20 is about 0.025 to about 0.15% weight/volume and the temperature of the assembly is about 37 °C; removing aliquots and measuring the percentage of steroid dissolved in each aliquot.
DETAILED DESCRIPTION OF THE INVENTION The precision and accuracy of dissolution testing is dependent upon strict observance of subtle parameters and controls. (Remington's
Pharmaceutical Sciences). The present invention finds that the dissolution medium is critical and controls the composition of the medium, namely the type of water, the surfactant and the solution's concentration. In addition, to the aforementioned factors, the method of preparing the dissolution medium (premixing time) can be critical with some surfactants.
The surfactant employed is polysorbate 20, a partially esterified cyclic derivative of sorbitol, a natural sugar. The surfactant's most popular use is in the preparation of pharmaceutical formulations it may have other uses. Polysorbate 20 is commercially available from a number of suppliers and due to the surfactant's susceptibility to degradation over time, USP (23/NF 18) has published standards for determining the suitability of the surfactant.
However the published values (hydroxyl, saponification, water, residue on ignition, arsenic, heavy metals and acid content values) do not guarantee suitability of polysorbate 20 for this dissolution test. ( See Donbrow, M. et al Journal of Pharmaceutical Sciences, 67, 12, pgs. 1676-81 1978). Although polysorbate 20 produced by a variety of manufacturers can be used, the preferred surfactant is "fresh" polysorbate 20 as described hereinafter.
It has been found herein that Polysorbate 20 which was more than two years old gave variable results in dissolution tests of the same lot of steroidal formulation. Although the surfactant was not expired (manufacturer's expiration date) and met accepted USP acid values (<2.2) variable test results were a problem. When 4 year old surfactant was employed, the number of hours of premixing was inversely proportional to the percentage of dissolved steroid. For example, in dissolution tests of tablets containing norgestimate, 4 year old surfactant was used and the dissolution solution was premixed for 96 hours. At 20 min the percentage of dissolved steroid was 46.5 to 56.6%. This test was repeated using the same steroid and surfactant, but reducing the premixing time to 24 hour and gave 81.2 to 90% as the percentage of dissolved norgestimate at 20 min. However when one year old polysorbate 20 was used, the length of time that the surfactant was premixed with the water did not affect the dissolution results within a single batch.
It has also been found that age alone is not the determinative factor for the suitability of polysorbate 20. Whether or not the polysorbate 20 was stored in the presence or absence of light, factors into the surfactant's usefulness for dissolution testing. Dissolution tests were run with 4 year old unprotected and light protected polysorbate 20 on single lots of steroidal formulations. These results were compared with dissolution runs with one year old polysorbate 20. The test results using the light protected material were within 4.5% of the test results obtained using one year old polysorbate. Whereas the results obtained using the unprotected material were only within 10.1% of the standard. Once again USP acid values could not be used to
predict the suitability of the surfactant, for the unprotected and the light protected material were below the USP cutoff of 2.2 (2.0 and 1.7 respectively). The USP guidelines make no mention of storing the surfactant in the absence of light. The guidelines only require storage in sealed containers.
Bearing all the aforementioned factors in mind, it is preferred herein to use fresh polysorbate 20: polysorbate that is less than 2 years old, which has been stored in the absence of light and has been stored under an inert atmosphere. It is possible to obtain reliable and reproducible dissolution test results using polysorbate 20 that does not meet all three criteria. However, the preferred polysorbate 20 is material that meets all three criteria.
In addition to the condition of the surfactant, the type of water, temperature of the dissolution medium and concentration of the surfactant affect dissolution testing. The preferred water is helium sparged deionized water, but bottled water may be substituted.
The preferred temperature of the dissolution medium is about 37 °C. However in vitro dissolution tests may be run from about 34 -42 °C. The type of paddle assembly used in the invention's in vitro test may vary, and those skilled in the art of dissolution testing may use apparatuses suitable to their needs. However a USP Paddle Assembly II (Volume 23) is the preferred assembly.
With respect to concentration of surfactant, Table A illustrates that dissolution rates increase with increasing surfactant concentration. The data in this table was generated by testing a single lot of steroid with different concentrations of polysorbate 20 in the following manner. Deionized water was premixed with the sufficient polysorbate 20 to give the indicated concentration over 16 h. This solution (600 mL) was placed in each of the reaction vessels of a USP Paddle Assembly II (vol 23/18), stirred at 75 r.p.m. and equilibrated to 37 °C. A norgestimate and ethinyl estradiol formulation was added to each vessel, samples were removed at 20 min and analyzed by routine HPLC methods for the percentage of dissolved norgestimate. The
first four runs used fresh polysorbate and the last run (*) used 4 year old surfactant. The data is represented as both the average % and the range of values obtained. As shown, the concentration of polysorbate 20 which give the narrowest range of values is 0.05% of fresh polysorbate 20. Therefore the preferred concentration of polysorbate 20 is 0.05%. Although the data below was obtained for norgestimate, similar results are expected for ethinyl estradiol, the other steriodal component of the formulation.
TABLE A
% Polysorbate 20 Average % Dissolved Range % Dissolved 0.125% 93.4 91.6-95.7 ( E 4.1 )
0.075% 91.0 86.6-94.3 ( E 7.7)
0.05% 80.9 78.1-82.1 ( E 4.0)
0.025% 71.8 66.8-75.9 ( E 9.1 )
*0.05% 83.4 79.4-90.6 ( E 11.2)
The following example is meant to illustrate the invention, not to limit it. Other embodiments will be obvious to those skilled in the art and are claimed by this invention. The identity of the compounds was confirmed by HPLC comparison with known standards. The amount of dissolved steriod was deterrmined by their HPLC area%. The polysorbate 20 used was "fresh" polysorbate as defined above.
Example 1
Deionized water was sparged with helium for at least 12 min. Fresh polysorbate 20 (3.0 g; Tween® 20) was placed in a 400 mL beaker and dissolved in sparged water (200 mL) at room temperature with the aid of mechanical stirring. The resulting solution was diluted with sparged water to 6L and stirred overnight at room temperature.
A portion of the resulting solution (600 mL) was added to each vessel of a USP Paddle Assembly II (vol 23/18), the solution was stirred at 75 r.p.m. and the temperature bath of said assembly and equilibrated to 37+ 0.5 °C. Tablets containing ethinyl estradiol (EE) and norgestimate (NGM) of five lots and a control (Lot B) were dropped into the equilibrated dissolution vessels (one table per vessel and 12 vessels/lot). Samples (10 mL) were taken at 15, 20 and 30 min. Said samples were analyzed for their % of dissolved steroids by HPLC and reported (TABLE B) as the average % dissolved and the range % dissolved. The individual lots correspond to tablets containing NGM/EE mg, in the following proportions: A= 0.215/0.035 mg, B= 0.250/0.035 mg, C= 0.180/0.035 mg, D=0.250/0.035 mg, E= 0.180/0.035 mg, F= 0.215/0.035 mg.
TABLE B
Claims
1. A method of measuring the dissolution rate of a solid steroidal pharmaceutical formulation, comprising:
1 ) adding said formulation to a paddle assembly containing an aqueous solution of polysorbate 20, where the concentration of polysorbate 20 is about 0.025% to about 0.15% weight/volume, the temperature of the assembly is about 37 °C;
2) removing aliquots and
3) measuring the percentage of steroid contained therein.
2. The method of claim 1 wherein the concentration of polysorbate 20 is about 0.025% to about 0.1 %.
3. The method of claim 1 wherein the solid steroidal pharmaceutical formulation contains norgestimate.
4. The method of claim 1 wherein the solid steroidal pharmaceutical formulation contains ethinyl estradiol.
5. The method of claim 1 wherein the polysorbate 20 is fresh polysorbate 20.
6. A method of measuring the dissolution rate of a solid steroidal pharmaceutical formulation, comprising:
1 ) adding said formulation to a paddle assembly containing an aqueous solution of fresh polysorbate 20, where the concentration of fresh polysorbate 20 is about 0.025% to about 0.10% weight/volume, the temperature of the assembly is about 37 °C;
2) removing aliquots and
3) measuring the percentage of steroid contained therein.
7. The method of claim 6 wherein the concentration of fresh polysorbate 20 is about 0.025% to about 0.06%.
8. The method of claim 7 wherein the solid steriodal pharmaceutical formulation contains norgestimate.
9. The method of claim 7 wherein the solid steriodal pharmaceutical formulation contains ethinyl estradiol.
10. A method of measuring the dissolution rate of a solid steroidal pharmaceutical formulation containing norgestimate, comprising:
1 ) adding said formulation to a paddle assembly containing an aqueous solution of polysorbate 20, where the concentration of polysorbate 20 is about 0.04% to about 0.06% weight/volume, the temperature of the assembly is about 37 °C;
2) removing aliquots and
3) measuring the percentage of steroid contained therein.
11. The method of claim 10 wherein the concentration of polysorbate 20 is about 0.05%.
12. A method of measuring the dissolution rate of a solid steroidal pharmaceutical formulation containing ethinyl estradiol, comprising:
1 ) adding said formulation to a paddle assembly containing an aqueous solution of polysorbate 20, where the concentration of polysorbate 20 is about 0.04% to about 0.06% weight/volume, the temperature of the assembly is about 37 °C;
2) removing aliquots and
3) measuring the percentage of steroid contained therein.
13. The method of claim 12 wherein the concentration of polysorbate 20 is about 0.05%.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002270951A CA2270951A1 (en) | 1996-11-07 | 1997-11-07 | A dissolution test method for solid steroidal pharmaceutical formulations |
| EP97946599A EP0937247A1 (en) | 1996-11-07 | 1997-11-07 | A dissolution test method for solid steroidal pharmaceutical formulations |
| AU51737/98A AU721983B2 (en) | 1996-11-07 | 1997-11-07 | A dissolution test method for solid steroidal pharmaceutical formulations |
| IL12976997A IL129769A0 (en) | 1996-11-07 | 1997-11-07 | A dissolution test method for solid steroidal pharmaceutical formulations |
| JP52181898A JP2001503867A (en) | 1996-11-07 | 1997-11-07 | Dissolution test method for solid steroidal pharmaceutical preparations. |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2988596P | 1996-11-07 | 1996-11-07 | |
| US60/029,885 | 1996-11-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1998020340A1 true WO1998020340A1 (en) | 1998-05-14 |
Family
ID=21851397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1997/020395 WO1998020340A1 (en) | 1996-11-07 | 1997-11-07 | A dissolution test method for solid steroidal pharmaceutical formulations |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0937247A1 (en) |
| JP (1) | JP2001503867A (en) |
| CN (1) | CN1236435A (en) |
| AU (1) | AU721983B2 (en) |
| CA (1) | CA2270951A1 (en) |
| IL (1) | IL129769A0 (en) |
| WO (1) | WO1998020340A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4151273A (en) * | 1974-10-31 | 1979-04-24 | The Regents Of The University Of California | Increasing the absorption rate of insoluble drugs |
| FR2722407A1 (en) * | 1994-06-30 | 1996-01-19 | Kolon Inc | Water-solubilised formulations of oil-soluble substances |
| EP0803250A1 (en) * | 1996-04-24 | 1997-10-29 | American Home Food Products, Inc. | Controlled release of steroids from sugar coatings |
-
1997
- 1997-11-07 JP JP52181898A patent/JP2001503867A/en active Pending
- 1997-11-07 IL IL12976997A patent/IL129769A0/en unknown
- 1997-11-07 AU AU51737/98A patent/AU721983B2/en not_active Ceased
- 1997-11-07 EP EP97946599A patent/EP0937247A1/en not_active Withdrawn
- 1997-11-07 CN CN97199513.3A patent/CN1236435A/en active Pending
- 1997-11-07 WO PCT/US1997/020395 patent/WO1998020340A1/en not_active Application Discontinuation
- 1997-11-07 CA CA002270951A patent/CA2270951A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4151273A (en) * | 1974-10-31 | 1979-04-24 | The Regents Of The University Of California | Increasing the absorption rate of insoluble drugs |
| FR2722407A1 (en) * | 1994-06-30 | 1996-01-19 | Kolon Inc | Water-solubilised formulations of oil-soluble substances |
| EP0803250A1 (en) * | 1996-04-24 | 1997-10-29 | American Home Food Products, Inc. | Controlled release of steroids from sugar coatings |
Non-Patent Citations (2)
| Title |
|---|
| KVORNING, I. ET AL: "Bioavailability of four estradiol suspensions with different particle-sizes - in vivo and in vitro correlation", DRUG DEV. IND. PHARM. (1981), 7(3), 289-303 CODEN: DDIPD8;ISSN: 0363-9045, XP000566262 * |
| SHAWKY, S. ET AL: "Ethinyl estradiol. Evaluation of marketed tablets and relevant studies on the enhancement of its dissolution rate", PHARM. IND. (1991), 53(11), 1069-75 CODEN: PHINAN;ISSN: 0031-711X, XP002056372 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU5173798A (en) | 1998-05-29 |
| CA2270951A1 (en) | 1998-05-14 |
| AU721983B2 (en) | 2000-07-20 |
| IL129769A0 (en) | 2000-02-29 |
| EP0937247A1 (en) | 1999-08-25 |
| JP2001503867A (en) | 2001-03-21 |
| CN1236435A (en) | 1999-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wolf et al. | Intracellular Ca2+ mobilization by arachidonic acid. Comparison with myo-inositol 1, 4, 5-trisphosphate in isolated pancreatic islets. | |
| Leighton et al. | Structure, composition, physical properties, and turnover of proliferated peroxisomes. A study of the trophic effects of Su-13437 on rat liver. | |
| Morris et al. | Ultrastructural preservation of the dense core of posterior pituitary neurosecretory granules and its implications for hormone release | |
| Schoenmakers et al. | Effects of Oestradiol‐17 β on the Ovaries of the Starfish Asterias rubens | |
| Sun et al. | Di (2-ethyl-hexyl) phthalate disrupts placental growth in a dual blocking mode | |
| Roubos et al. | Control of the activities of the neurosecretory light green and Caudo-Dorsal Cells and of the endocrine dorsal bodies by the lateral lobes in the freshwater snail Lymnaea stagnalis (L.) | |
| de Castro Bezerra et al. | Development of a dissolution method for gliclazide modified-release tablets using USP apparatus 3 with in vitro–in vivo correlation | |
| Sprockel et al. | Evaluation of sustained release aqueous suspensions containing microencapsulated drug-resin complexes | |
| WO1998020340A1 (en) | A dissolution test method for solid steroidal pharmaceutical formulations | |
| Campbell et al. | Differential distribution of an estrogen receptor in the submandibular and parotid salivary glands of female rats | |
| Desjardins et al. | In vitro binding and autoradiographic localization of human chorionic gonadotropin and follicle stimulating hormone in rat testes during development | |
| MXPA05002761A (en) | Methods of measuring the dissolution rates of an analyte in a non-aqueous liquid composition. | |
| EP1275379A2 (en) | Basic granulate comprising (7 alpha, 17 alpha)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one | |
| Kessler et al. | No background concentrations of di (2-ethylhexyl) phthalate and mono (2-ethylhexyl) phthalate in blood of rats | |
| Stupak et al. | Biopharmaceutical and physicochemicai studies on reserpine-polyvinylpyrrolidone coprecipitates | |
| Pfeifer et al. | Stimulation of cellular autophagy by parathyroid hormone and cyclic adenosine 3′, 5′: Monophosphate in isolated tubular fragments from the rat’s kidney cortex | |
| CN114527230A (en) | Method for detecting concentration of vitamin A and vitamin E in human dry blood spots | |
| Jovanović et al. | Protective action of 17β-estradiol in cardiac cells: implications for hyperkalemic cardioplegia | |
| Schneider et al. | Species differences in developmental toxicity of epoxiconazole and its relevance to humans | |
| Batra | Subcellular Distribution and Cytosolic Receptors of Progesterone and of Estradiol-17 β in the Rabbit Myometrium: Effect of Progesterone Treatment | |
| JPH08505223A (en) | Control reagent containing hydroxylamine or antioxidant | |
| Smajdor et al. | Voltammetric determination of drospirenone on mercury film electrode | |
| Burczynski et al. | Effect of nitric oxide on albumin-palmitate binding | |
| Murr et al. | Twenty-week exposures to the drinking water disinfection by-product dibromoacetic acid: reproductive cyclicity and steroid concentrations in the female Sprague–Dawley rat | |
| ZA200406042B (en) | Immediate-release pharmaceutical dosage form comprising polymorphous tibolone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 97199513.3 Country of ref document: CN |
|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 51737/98 Country of ref document: AU |
|
| ENP | Entry into the national phase |
Ref document number: 2270951 Country of ref document: CA |
|
| ENP | Entry into the national phase |
Ref document number: 1998 521818 Country of ref document: JP Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1997946599 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1997946599 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWG | Wipo information: grant in national office |
Ref document number: 51737/98 Country of ref document: AU |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1997946599 Country of ref document: EP |